Knight wins Colombian approval for TAVALISSE in chronic ITP

Sep 1, 2026 22:00 (21d ago)

Verifying

Knight Therapeutics received INVIMA approval for TAVALISSE in adult chronic ITP patients.
August 31, 2026 marked the approval date cited in the prescribing information.
Knight launched TAVALISSE in Mexico in May 2026 and plans Colombian sales in 2027.

The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.